US 12,440,489 B2
Organic compounds
Wei Yao, New Milford, NJ (US); Peng Li, New Milford, NJ (US); Robert Davis, San Diego, CA (US); Sharon Mates, New York, NY (US); Kimberly Vanover, New York, NY (US); and Gretchen Snyder, New York, NY (US)
Assigned to INTRA-CELLULAR THERAPIES, INC., Bedminster, NJ (US)
Filed by INTRA-CELLULAR THERAPIES, INC., New York, NY (US)
Filed on Nov. 6, 2023, as Appl. No. 18/502,460.
Application 18/502,460 is a continuation of application No. 17/015,883, filed on Sep. 9, 2020, granted, now 11,844,757.
Application 17/015,883 is a continuation of application No. 16/276,331, filed on Feb. 14, 2019, granted, now 10,799,500, issued on Oct. 13, 2020.
Application 16/276,331 is a continuation of application No. 15/660,615, filed on Jul. 26, 2017, granted, now 10,245,260, issued on Apr. 2, 2019.
Application 15/660,615 is a continuation in part of application No. PCT/US2017/015178, filed on Jan. 26, 2017.
Claims priority of provisional application 62/440,130, filed on Dec. 29, 2016.
Claims priority of provisional application 62/287,264, filed on Jan. 26, 2016.
Prior Publication US 2024/0165111 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 31/445 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); C07D 241/40 (2006.01); C07D 471/16 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 9/0019 (2013.01); A61K 9/16 (2013.01); A61K 31/445 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); C07D 241/40 (2013.01); C07D 471/16 (2013.01)] 17 Claims
 
1. A method for the treatment of a central nervous system disorder, comprising administering to a patient in need of such treatment, a compound of a Formula I:

OG Complex Work Unit Chemistry
wherein:
X is —NH—;
L is O; and
Z is —O—;
in toluenesulfonic acid addition salt form;
wherein the central nervous system disorder is selected from the group consisting of obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), general anxiety disorder, social anxiety disorder, panic disorder, agoraphobia, compulsive gambling disorder, compulsive eating disorder, body dysmorphic disorder, hypochondriasis, pathological grooming disorder, kleptomania, pyromania, attention deficit-hyperactivity disorder (ADHD), attention deficit disorder (ADD), impulse control disorder, pain disorder, chronic fatigue, opiate dependency, cocaine dependency, amphetamine dependency, alcohol dependency, substance addiction, substance-use disorder, substance-abuse disorder, and combinations thereof;
wherein said patient is not responsive to or cannot tolerate the side effects from treatment with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or antipsychotic agents.